Beta Drugs Past Earnings Performance
Past criteria checks 3/6
Beta Drugs has been growing earnings at an average annual rate of 35.1%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 30.7% per year. Beta Drugs's return on equity is 24.5%, and it has net margins of 13.6%.
Key information
35.1%
Earnings growth rate
34.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 30.7% |
| Return on equity | 24.5% |
| Net Margin | 13.6% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20
Revenue & Expenses BreakdownBeta
How Beta Drugs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 2,560 | 348 | 254 | 0 |
| 30 Jun 23 | 2,416 | 327 | 249 | 0 |
| 31 Mar 23 | 2,271 | 307 | 243 | 0 |
| 31 Dec 22 | 2,176 | 298 | 226 | 0 |
| 30 Sep 22 | 2,081 | 289 | 210 | 0 |
| 30 Jun 22 | 1,960 | 269 | 190 | 0 |
| 31 Mar 22 | 1,838 | 248 | 170 | 0 |
| 31 Dec 21 | 1,683 | 216 | 156 | 0 |
| 30 Sep 21 | 1,528 | 183 | 143 | 0 |
| 30 Jun 21 | 1,345 | 150 | 132 | 0 |
| 31 Mar 21 | 1,161 | 117 | 121 | 0 |
| 31 Dec 20 | 1,058 | 106 | 119 | 0 |
| 30 Sep 20 | 956 | 95 | 103 | 0 |
| 30 Jun 20 | 932 | 94 | 99 | 0 |
| 31 Mar 20 | 908 | 94 | 110 | 0 |
| 30 Sep 19 | 832 | 97 | 89 | 0 |
| 30 Jun 19 | 746 | 89 | 76 | 0 |
| 31 Mar 19 | 659 | 80 | 64 | 0 |
| 31 Mar 18 | 506 | 68 | 30 | 0 |
| 31 Mar 17 | 417 | 43 | 53 | 0 |
| 31 Mar 16 | 264 | 11 | 32 | 0 |
| 31 Mar 15 | 3 | -1 | 1 | 0 |
| 31 Mar 14 | 14 | 0 | 2 | 0 |
Quality Earnings: BETA has high quality earnings.
Growing Profit Margin: BETA's current net profit margins (13.6%) are lower than last year (13.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BETA's earnings have grown significantly by 35.1% per year over the past 5 years.
Accelerating Growth: BETA's earnings growth over the past year (20.2%) is below its 5-year average (35.1% per year).
Earnings vs Industry: BETA earnings growth over the past year (20.2%) did not outperform the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: BETA's Return on Equity (24.5%) is considered high.